Biomarkers for the early detection of breast cancer

Patent metadata

Field	Value
Publication number	US-9857374-B2
Application number	US-201113809695-A
Country	US
Kind code	B2
Filing date	Aug 15, 2011
Priority date	Aug 13, 2010
Publication date	Jan 2, 2018
Grant date	Jan 2, 2018

Abstract

The present invention provides reagents and methods for breast cancer detection.

First claim

We claim:

1. A method comprising;
(a) contacting a serum or plasma sample obtained from a subject having or at risk of having breast cancer with a polypeptide probe set bound to a surface of a solid support, wherein the polypeptide probe set comprises CTBP1 polypeptide (SEQ ID NO: 29) or an antigenic fragment thereof, BDNF (SEQ ID NO: 17) or an antigenic fragment thereof, GPR157 (SEQ ID NO: 43) or an antigenic fragment thereof, and one or more additional polypeptides selected from the group consisting of ATP6AP1 (SEQ ID NO: 13), PDCD6IP (SEQ ID NO: 21), DBT (SEQ ID NO: 25), CSNK1E (SEQ ID NO: 9), FRS3 (SEQ ID NO: 3), RAC3 (SEQ ID NO: 15), HOXD1 (SEQ ID NO: 7), SF3A1 (SEQ ID NO: 1), C15orf48 (SEQ ID NO: 35), MYOZ2 (SEQ ID NO: 33), EIF3E (SEQ ID NO: 39), BAT4 (SEQ ID NO: 5), ATF3 (SEQ ID NO: 19), BMX (SEQ ID NO: 45), RAB5A (SEQ ID NO: 23), UBAP1 (SEQ ID NO: 47), SOX2 (SEQ ID NO: 31), ZMYM6 (SEQ ID NO: 41), SLC33A1 (SEQ ID NO: 11), TRIM32 (SEQ ID NO: 37), ALG10 (SEQ ID NO: 27), TFCP2 (SEQ ID NO: 49), SERPINH1 (SEQ ID NO: 51), SELL (SEQ ID NO: 55), ZNF510 (SEQ ID NO: 53), and antigenic fragments thereof; wherein the contacting occurs under conditions whereby antibodies, if present in the bodily fluid, selectively bind to the polypeptides bound to the surface;
(b) detecting presence of antibodies to the polypeptides in the sample;
wherein the presence of antibodies in the sample to the one or more polypeptides is used to diagnose breast cancer in the subject, and wherein detecting comprises normalizing intensities for each polypeptide of the probe set and comparing normalized intensities with a control using partial area under a receiver operating characteristic curve (pAUC) with a false positive rate no greater than 5 percent; and
(c) administering a therapeutic agent to the subject to treat the breast cancer.

2. The method of claim 1 , wherein the polypeptide probe set further comprises ATP6AP1 (SEQ ID NO: 13), or an antigenic fragment thereof.

3. The method of claim 1 , wherein the subject has one or more of a lump in breast tissue, lymph nodes, or armpit; changes in breast size or shape, skin dimpling, nipple inversion, spontaneous single-nipple discharge, a family/personal history of breast cancer, or the subject is a carrier of a mutation in BRCA.

4. The method of claim 1 , wherein the breast cancer is Stage I or Stage II breast cancer.

5. The method of claim 1 , wherein the detecting comprises use of a labeled antibody.

6. The method of claim 1 , wherein the subject is further tested for the presence of breast cancer using a technique selected from the group consisting of mammography, biopsy, or magnetic resonance imaging.

7. The method of claim 1 , wherein the polypeptide probe set further comprises two or more additional polypeptides selected from the group recited in claim 1 .

8. The method of claim 1 , wherein each polypeptide of the polypeptide probe set is bound to the surface using Nucleic Acid Programmable Protein Array (NAPPA) technology.

Assignees

• Labaer Joshua
• Anderson Karen Sue
• Wallstrom Garrick
• Sibani Sahar
• Ramachandran Niroshan
• Arizona Board Of Regents A Body Corporate Acting For And On Behalf Of Arizona State Univ
• Harvard College
• Dana Farber Cancer Inst Inc

Inventors

• Labaer Joshua
• Anderson Karen Sue
• Wallstrom Garrick
• Sibani Sahar
• Ramachandran Niroshan

Classifications

• G01N33/57515 Primary

  of the breast · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• G01N33/57415 Primary

  Physics · mapped topic

• C40B40/10

  Libraries containing peptides or polypeptides, or derivatives thereof · CPC title